Replies to post #1542 on Cocrystal Pharma Inc (COCP)

[mick]

$COCP, Upcoming Milestones Expected to Drive Value

Q1 2020 Hepatitis C Release Final Report on Phase 2a U.S. Trial
Q2 2020 Noro Preclinical Lead Molecule Selection
Q3 2020 Platform In-License New Lead Molecule
Q4 2020
Influenza A
Complete Preclinical IND-Enabling Studies
Regulatory Submission (IND or European Counterpart)
Commence Phase 1a Study
Merck A/B Influenza A/B Lead Molecule Selection
H2 2020 Hepatitis C Commence Phase 2b Enabling Toxicology Study
Q3 2021 Noro Regulatory Submission (IND or European Counterpart)
Ongoing potential for licensing deals across the pipeline
Q2 2019 Influenza A Commence GLP Toxicology Studies ?
Q3 2019 Influenza Present Preclinical Data at ISIRV ?
Q4 2019
Hepatitis C
Present at 26th International Symposium on Hepatitis C Virus and Related Viruses ?
Present Data at HCV 2019 and AASLD Scientific Conference

Ongoing potential for licensing deals across the pipeline